Metastatic Breast Cancer, Version 1.2012
- 5 July 2012
- journal article
- practice guideline
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 10 (7), 821-829
- https://doi.org/10.6004/jnccn.2012.0086
Abstract
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.Keywords
This publication has 14 references indexed in Scilit:
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancerMedical Oncology, 2010
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.Journal of the National Comprehensive Cancer Network, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- HER2gene status in primary breast cancers and matched distant metastasesBreast Cancer Research, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- HER2 Testing in Breast Cancer: NCCN Task Force Report and RecommendationsJournal of the National Comprehensive Cancer Network, 2006
- Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinomaCancer, 2005
- Reporting results of cancer treatmentCancer, 1981